Kazuto Nishio

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 658 citations

Cetuximab Sensitivity, Oncology, Erbb2 Signaling +15

Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.

Nobuhiro Nishiyama, Souichiro Okazaki, Horacio Cabral et al. · PubMed · 2003 · 602 citations

Engineering, Solid Tumors, Biomedical Engineering +21

Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

Hideharu Kimura, Kazuo Kasahara, Makoto Kawaishi et al. · Clinical Cancer Research · 2006 · 324 citations · Full text

Non–small-cell Lung Cancer, Serum Dna, Molecular Diagnostic Techniques +14

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

Nobuyuki Katakami, Shinji Atagi, Kōichi Goto et al. · Journal of Clinical Oncology · 2013 · 323 citations · Full text

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Koji Haratani, Hidetoshi Hayashi, Taro Tanaka et al. · Annals of Oncology · 2017 · 291 citations · Full text

Tumor Immune Microenvironment, Cancer Immunosurveillance, Medicine +11